Global Ursodeoxycholic Acid API Market Growth 2025-2031

The global Ursodeoxycholic Acid API market size is predicted to grow from US$ 635 million in 2025 to US$ 1088 million in 2031; it is expected to grow at a CAGR of 9.4% from 2025 to 2031.

Ursodeoxycholic Acid is also known as ursodiol (USAN). Ursodeoxycholic acid (3α, 7β-2-hydroxy-5β-bile acid, UDCA) was first found in the bile of a black bear. Ursodeoxycholic Acid is an important clinical drug in the treatment of gallstones, cholecystitis, PBC, and PSC and has broad market prospects. In previous work, ursodeoxycholic acid was prepared by traditional organic synthesis. In this report, the Ursodeoxycholic Acid we mentioned is Ursodeoxycholic Acid API. In addition, the CAS number is 128-13-2.

The growing prevalence of liver diseases, such as primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and certain forms of liver cirrhosis, serves as a significant driver for the Ursodeoxycholic Acid (UDCA) API market. As more individuals are diagnosed with these conditions due to improved medical awareness and diagnostic techniques, the demand for effective treatments like UDCA increases. UDCA has demonstrated efficacy in managing and alleviating symptoms of these liver diseases, positioning it as a valuable therapeutic option. The rising global burden of liver disorders, often associated with factors like aging and lifestyle changes, provides a sustained demand for UDCA API as a key component in manufacturing medications to address these conditions.

However, the UDCA API market faces several challenges, with regulatory hurdles and price pressures being significant constraints. The stringent approval requirements and the need for high-quality production standards in API manufacturing can delay the market entry of new players and increase operational costs. Furthermore, with the increasing production of generic UDCA products, competition has intensified, leading to a decrease in profit margins for manufacturers of branded UDCA drugs. Another challenge is the limited scope of UDCA applications, as the drug is effective primarily for a specific set of liver conditions, limiting its broader market appeal. Additionally, supply chain disruptions and raw material price fluctuations for manufacturing UDCA can affect the availability and cost-effectiveness of APIs, further complicating market dynamics.

Global key players of Ursodeoxycholic Acid API include ICE, Daewoong Chemical, PharmaZell GmbH and Zhongshan Bailing, etc. The top four players hold a share about 60%. APAC is the largest market, has a share about 50%. In terms of product type, Synthetic UDCA is the largest segment, occupied for a share of about 98%, and in terms of application, Pharmacy has a share about 90 percent.

LP Information, Inc. (LPI) ' newest research report, the “Ursodeoxycholic Acid API Industry Forecast” looks at past sales and reviews total world Ursodeoxycholic Acid API sales in 2024, providing a comprehensive analysis by region and market sector of projected Ursodeoxycholic Acid API sales for 2025 through 2031. With Ursodeoxycholic Acid API sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Ursodeoxycholic Acid API industry.

This Insight Report provides a comprehensive analysis of the global Ursodeoxycholic Acid API landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Ursodeoxycholic Acid API portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Ursodeoxycholic Acid API market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Ursodeoxycholic Acid API and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Ursodeoxycholic Acid API.

This report presents a comprehensive overview, market shares, and growth opportunities of Ursodeoxycholic Acid API market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Synthetic UDCA
Extraction UDCA

Segmentation by Application:
Pharmacy
Health Products

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
ICE
Mitsubishi Tanabe Pharma
Daewoong Chemical
PharmaZell GmbH
Zhongshan Bailing
Dipharma Francis
Grindeks
Suzhou Tianlv
Yun Gang Bio

Key Questions Addressed in this Report

What is the 10-year outlook for the global Ursodeoxycholic Acid API market?

What factors are driving Ursodeoxycholic Acid API market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Ursodeoxycholic Acid API market opportunities vary by end market size?

How does Ursodeoxycholic Acid API break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.